Showing results (131-140 of 144) with videos related to

Sort By:
Pageof 15
Journal of the National Comprehensive Cancer Network : JNCCN|June 11, 2026
Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter StudyNiels Heersche, Sofía L J Peeters, Doortje Böhm, et al.
The British Journal of Surgery|July 19, 2023
Phase I study of intraperitoneal irinotecan combined with palliative systemic chemotherapy in patients with colorectal peritoneal metastasesRuben A G van Eerden, Nadine L de Boer, Job P van Kooten, et al.
European Journal of Cancer (Oxford, England : 1990)|January 8, 2022
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patientsEmma C Hulshof, Mirjam de With, Femke M de Man, et al.
The Lancet Regional Health. Europe|March 4, 2026
Survival of patients with colorectal or pancreatic cancer who received <i>UGT1A1</i> genotype-guided dosing of irinotecan in the Netherlands (2017-2024): a retrospective, multicentre cohort studySofía L J Peeters, Niels Heersche, Doortje Böhm, et al.
Clinical Pharmacology and Therapeutics|April 9, 2022
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical StudyMirjam de With, Jonathan Knikman, Femke M de Man, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2023
Survival of Patients With Cancer With <i>DPYD</i> Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair AnalysisJonathan E Knikman, Tycho A Wilting, Marta Lopez-Yurda, et al.
Intensive & Critical Care Nursing|September 2, 2020
Prevalence and management of delirium in intensive care units in the Netherlands: An observational multicentre studyElke Berger, Evert-Jan Wils, Piet Vos, et al.
Genome Medicine|August 15, 2024
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYDJonathan E Knikman, Qinglian Zhai, Carin A T C Lunenburg, et al.
The Lancet. Oncology|October 24, 2018
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2018
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapyLinda M Henricks, Carin A T C Lunenburg, Femke M de Man, et al.
Pageof 15